Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00

Trevi Therapeutics (NASDAQ:TRVI) had its price target boosted by Oppenheimer from $12.00 to $20.00 in a research report released on Tuesday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities analysts have also issued reports about the stock. Needham & Company LLC raised their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright raised their price objective on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday. D. Boral Capital restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Friday, March 7th. Finally, Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a research report on Monday. Seven research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $15.94.

Trevi Therapeutics Trading Down 0.2 %

TRVI stock opened at $6.29 on Tuesday. The firm has a 50 day moving average of $4.30 and a 200-day moving average of $3.60. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The firm has a market capitalization of $483.49 million, a P/E ratio of -14.30 and a beta of 0.90.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 24.37% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TRVI. GSA Capital Partners LLP purchased a new position in shares of Trevi Therapeutics during the third quarter worth approximately $409,000. Oppenheimer & Co. Inc. increased its stake in shares of Trevi Therapeutics by 34.7% in the third quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock worth $274,000 after buying an additional 21,128 shares during the period. MAI Capital Management increased its stake in shares of Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after buying an additional 8,789 shares during the period. Intech Investment Management LLC purchased a new position in shares of Trevi Therapeutics in the third quarter worth $63,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.